Peterlin P, Jullien M. Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies. Haematologica; https://doi.org/10.3324/haematol.2025.287378 [Early view].